TACE联合131I美妥昔单克隆抗体灌注治疗原发性肝癌患者近期疗效研究

doi:10.3969/j.issn.1672-5069.2020.06.030

摘要/Abstract

摘要： 目的探讨经肝动脉栓塞化疗(TACE)介入术时加入¹³¹I美妥昔单克隆抗体灌注治疗原发性肝癌患者的近期疗效及影响预后的因素。方法 2016年8月～2017年12月我院治疗的原发性肝癌患者84例,被分成对照组42例和观察组42例,分别给予TACE介入术治疗和在TCACE术灌注化疗药物后继续给予¹³¹Ⅰ美妥昔单克隆抗体灌注。术后随访12个月,采用多元Logistics回归分析影响患者预后的危险因素。结果在治疗后3个月,观察组疾病缓解率和疾病控制率分别为73.8%和90.5%,显著高于对照组的50.0%和73.8%(P<0.05);观察组不良反应发生率为28.6%,与对照组的33.3%比,差异无统计学意义(P<0.05);术后,观察组血清甲胎蛋白水平为(418.7±67.3)ng/ml,显著低于对照组【(504.7±71.5)ng/ml,P<0.05】,而血清白蛋白水平为(37.7±3.4)g/L,显著高于对照组【(34.2±3.3)g/L,P<0.05】;在治疗后12个月,观察组死亡7例(16.7%),对照组死亡12例(28.6%,P<0.05);经多元Logistics回归分析,存在门静脉癌栓、肿瘤直径 >5 cm和TNM分期Ⅳ期是导致患者出现不良预后的危险因素(OR=2.354,P=0.027;OR=2.670,P=0.011;OR=3.071,P=0.004)。结论在采用TACE治疗原发性肝癌患者时,加入¹³¹I美妥昔单克隆抗体灌注有助于提高近期疗效,但对存在门静脉癌栓、肿瘤直径 >5 cm和TNM分期较晚的患者,治疗效果仍较差。

关键词: 原发性肝癌, 经肝动脉栓塞化疗, ¹³¹I美妥昔单克隆抗体, 预后影响因素

Abstract: Objective To explore the short-term curative effect of transcatheter arterial chemoembolization (TACE) with ¹³¹I mentuximab perfusion in the treatment of patients with primary liver cancer (PLC) and influencing factors of prognosis. Methods Eighty-four patients with PLC were admitted to our hospital from August 2016 through December 2017, and were divided into control group and observation group, with 42 cases in each group. The patients with PLC in the control group were treated with TACE, and those in the observation received TACE and ¹³¹I mentuximab perfusion. All patients were followed-up for 12 months. The risk factors affecting prognosis were analyzed by multivariate Logistics regression analysis. Results At the end of three months, the remission rate and control rate in the observation group were 73.8% and 90.5%, significantly higher than 50.0% and 73.8%, respectively, in the control(P<0.05);the incidence of side effects was 28.6% in the observation group, not significantly different compared to 33.3% in the control group (P>0.05); serum alpha-fetoprotein level in the observation group was (418.7±67.3) ng/ml, much lower than [(504.7±71.5) ng/ml, P<0.05] in the control, and serum albumin level was (37.7±3.4) g/L, significantly higher than [(34.2±3.3) g/L, P<0.05] in the control; at the end of 12 month, seven patients(16.7%)in the observation died, while twelve patients (28.6%)in the control died (P<0.05); the multivariate Logistics regression analysis showed that the portal vein tumor thrombus, tumor diameter greater than 5 cm and advanced stage of TNM were the risk factors of poor prognosis(OR=2.354, P=0.027; OR=2.670, P=0.011; OR=3.071, P=0.004). Conclusion The short-term curative effect of TACE with¹³¹I mentuximab perfusion in the treatment of patients with PLC is promising, and some factors such as portal vein tumor thrombus, large tumor diameter and advanced TNM staging might hint poor prognosis.

Key words: Primary liver cancer, Transcatheter arterial chemoembolization, ¹³¹I mentuximab, Prognosis

郭文成, 李娜, 王芳, 张宁, 刘燕. TACE联合¹³¹I美妥昔单克隆抗体灌注治疗原发性肝癌患者近期疗效研究[J]. 实用肝脏病杂志, 2020, 23(6): 877-880.

Guo Wencheng, Li Na, Wang Fang, et al. Short-term efficacy oftranscatheter arterial chemoembolization with ¹³¹I methicone monoclonal antibody in the treatment of patients with primary liver cancer[J]. Journal of Practical Hepatology, 2020, 23(6): 877-880.

参考文献

[1] 陈亚平, 姜晓晓, 蒋冠, 等. TACE联合SBRT治疗原发性肝癌的Meta分析. 国际肿瘤学杂志, 2015, 42(3):187.
[2] Kang W H , Hwang S , Song G W , et al. Prognostic effect of TACE-induced complete pathological response in patients undergone liver resection and transplantation for hepatocellular carcinoma . Liver Transpl, 2017, 23(6):781-790.
[3] 中国抗癌协会肝癌专业委员会. 原发性肝癌规范化病理诊断指南(2015年版) . 中华肝胆外科杂志, 2015, 21(3):865-872.
[4] 刘群轶, 余国政, 杨广宁,等. 冷循环微波消融联合肝动脉灌注化疗栓塞治疗原发性肝癌患者疗效及安全性研究. 实用肝脏病杂志, 2017, 20(3):316-319.
[5] Sven L , Maximilian S H , CatherineL , et al. IL-6 and IL-8 serum levels predict tumor response and overall survival after TACE for primary and secondary hepatic malignancies . Int J Molr Sci, 2018, 19(6):1766-1770.
[6] Sandow T , Albar A , Gulotta P , et al. Tumor grade and primary treatment response following DEB-TACE for hepatocellular carcinoma based on liver explant. J Vasc Intervl Radiol, 2017, 28(2):125-128.
[7] 牛焕章, 肖全平, 李东民,等. ¹²⁵I粒子植入联合肝动脉化疗栓塞治疗中晚期原发性肝癌的近期疗效. 中华肝胆外科杂志, 2017, 23(11):776-781.
[8] Fan F , Qiyu J , Hui J , et al. Which is the best combination of TACE and sorafenib for advanced hepatocellular carcinoma treatment A systematic review and network meta-analysis. Pharmacoll Res, 2018, 22(1):129-131.
[9] Gonzalez W , Idée JM, Ballet S. Comment on “in vivo drug delivery performance of lipiodol-based emulsion or drug-eluting beads in patients with hepatocellular carcinoma” . Molr Pharm, 2018, 15(1):332-335.
[10] 肖建新陈雷. TACE联合¹³¹I美妥昔单克隆抗体治疗介入术后复发的肝细胞癌患者疗效及安全性分析 . 实用肝脏病杂志, 2015, 18(6):656-658.
[11] Liu F , Meng Z , Shao G , et al. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study . Molr Biol Rep, 2017, 44(1):149-158.
[12] 张慧贤, 马向明, 付庆江, 等. 经肝动脉化疗栓塞联合经皮微波消融序贯治疗中晚期肝癌的疗效及预后分析 . 肝脏, 2017, 22(5):431-434.
[13] 邓兰, 蒋益兰, 江摩,等. TACE联合中药治疗原发性肝癌患者初步临床研究.实用肝脏病杂志, 2017, 20(2):242-243.
[14] Lan T , Chang L , Mn R , et al. Comparativeefficacy of interventional therapies for early-stage hepatocellular carcinoma: A PRISMA-compliant systematic review and network Meta-analysis . Medicine, 2016, 95(15):e3185.
[15] 赖军明, 胡爽, 林红,等. 重组人血管内皮抑制素联合TACE治疗中晚期原发性肝癌近期疗效的荟萃分析. 中华肝胆外科杂志, 2019, 25(5):358-362.
[16] 刘亚, 曾建挺, 张艳林, 等. 灌注式热化疗联合微球在原发性肝癌介入治疗中的价值 . 中国医学物理学杂志, 2018, 35(11):105-110.
[17] Lucatelli P , Ginnani Corradini L , De Rubeis G , et al. Balloon-occluded transcatheter arterial chemoembolization (b-TACE) for hepatocellular carcinoma performed with polyethylene-glycol epirubicin-loaded drug-eluting embolics: Safety and preliminary results . Cardiovasc Intervent Radiol, 2019, 19(6):853-862.
[18] 范文哲, 卢鸣剑, 崔伟,等. ¹³¹I-美妥昔单抗联合肝动脉化疗栓塞治疗肝细胞癌的疗效与安全性的Meta分析. 中华普通外科学文献:电子版, 2016, 10(5):381-386.

TACE联合¹³¹I美妥昔单克隆抗体灌注治疗原发性肝癌患者近期疗效研究

Short-term efficacy oftranscatheter arterial chemoembolization with ¹³¹I methicone monoclonal antibody in the treatment of patients with primary liver cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李晓燕, 胡和平. 加强肝癌内科队伍建设,重视肝癌内科规范化和个性化诊疗决策[J]. 实用肝脏病杂志, 2021, 24(1): 1-3.
[2]	周新民, 丁小鹏. 基础肝病治疗在原发性肝癌综合治疗中的重要作用[J]. 实用肝脏病杂志, 2021, 24(1): 4-6.
[3]	张雪, 胥莹, 安文慧, 张帮婷, 杨雪芳. 五种评分系统判断TACE术治疗原发性肝癌患者发生肝功能不全效能比较研究[J]. 实用肝脏病杂志, 2021, 24(1): 111-114.
[4]	乔敏, 赵一鉴, 张建巧, 景赟杭. TACE联合射频消融治疗原发性肝癌患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 119-122.
[5]	李亚敏, 王瑞婷, 王瑛瑛. 冷循环射频消融术治疗原发性肝癌患者疗效及外周血Treg细胞的变化观察[J]. 实用肝脏病杂志, 2021, 24(1): 123-126.
[6]	王飞雪, 于君. 肠道菌群与原发性肝癌[J]. 实用肝脏病杂志, 2020, 23(6): 769-772.
[7]	胡侠, 翟笑枫, 顾伟, 卢成鸿. 射波刀联合经肝动脉化疗栓塞治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(6): 881-884.
[8]	韩鹏伟, 王虎明, 赵天永. AFP阴性原发性肝癌临床特征及预后因素分析[J]. 实用肝脏病杂志, 2020, 23(5): 715-718.
[9]	孟海生, 胡冬梅, 王海涛, 顾金凤, 赵静, 梁啸寒. 应用超声单模态融合成像技术指导微波消融治疗原发性肝癌即时疗效评价的价值研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 572-575.
[10]	全亚宁, 商晓杰, 孟璇, 高榆秀. 实时超声造影和融合影像导航下微波消融与手术治疗小肝癌患者疗效比较^*[J]. 实用肝脏病杂志, 2020, 23(4): 581-584.
[11]	吴杰,谢丽响,修金. 影像学检查评估TACE治疗的原发性肝癌患者术后残余肿瘤活性价值研究[J]. 实用肝脏病杂志, 2020, 23(3): 419-422.
[12]	李颖, 黄海清, 薛富善, 池萍, 李丽. 瑞芬太尼复合丙泊酚靶控输注麻醉用于肝部分切除术患者临床效果研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 272-275.
[13]	陈亮, 段海峰, 余红星. SMI、CDFI和增强CT检查TACE术治疗的原发性肝癌患者癌组织血供显像效果比较^*[J]. 实用肝脏病杂志, 2020, 23(1): 90-93.
[14]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[15]	刘杏, 赵树立, 张殿隆. 七氟烷吸入时机对肝脏部分切除术患者肝脏缺血再灌注损伤的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 728-731.